

Jorge S. Reis-Filho, MD PhD FRCPath

Jorge S. Reis-Filho, MD PhD FRCPath, holds a joint medical degree from University of Porto, Portugal and Universidade Federal do Parana, Brazil. After finishing his histopathology training at the Institute of Molecular Pathology and Immunology, University of Porto, Portugal, he did his PhD on breast cancer molecular pathology at the Breakthrough Research Centre at The Institute of Cancer Research/ Royal Marsden Hospital in London, UK, where he was appointed Team Leader of the Molecular Pathology Laboratory in 2006. In 2007, Dr. Reis-Filho was awarded the CL Oakley Lectureship by the Pathological Society of Great Britain and Ireland and the BACR Translational Research Award. In 2010, Dr. Reis-Filho was awarded the 2010 Ramzi Cotran Young Investigator Award by the United States and Canadian Academy of Pathology and the Future Leaders Prize by Cancer Research UK. Dr. Reis-Filho is the youngest ever Fellow of The Royal College of Pathologists to have become a member by published works. In 2012, Dr. Reis-Filho took the position of Member at the Department of Pathology and Affiliate Member of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center in New York, USA, and in 2016, he was appointed Chief of Experimental Pathology and Director of the Experimental Pathology Fellowship Program. Dr. Reis-Filho has published over 480 peer reviewed articles, is an associate editor of the Journal of the National Cancer Institute and *npj Breast Cancer*, a member of the editorial board of *Genome Biology*, and a member of the expert panel of the World Health Organization for the classification of breast tumors and soft tissue tumors.

Dr. Reis-Filho's research interests are in the development of a predictive breast cancer classification system based on the oncogenic drivers of special histologic types of breast and salivary gland cancers, and in the understanding of the causes and impact of intra-tumor genetic heterogeneity in cancers. His group has approached these aims using a combination of traditional pathology approaches with high-throughput genomics methods. He has led projects that resulted in the development of novel single cell sequencing methods that can be applied to archival tissue samples, and has employed these methods to investigate the impact of intra-tumor genetic heterogeneity in the progression from *in situ* to invasive breast cancer and in therapy resistance. Dr. Reis-Filho has contributed to the use of methods for circulating cell-free tumor DNA in plasma in breast cancer and to the development of 'high-intensity' assays for breast cancer detection and monitoring.